Myelosuppression by sunitinib is flt-3 genotype dependent.
van Erp
N P
NP
Mathijssen
R H J
RH
van der Veldt
A A
AA
Haanen
J B
JB
Reyners
A K L
AK
Eechoute
K
K
Boven
E
E
Wessels
J A M
JA
Guchelaar
H-J
HJ
Gelderblom
H
H
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007970:Leukopenia / Q000139:chemically induced* / Q000235:genetics*; D011110:Polymorphism, Genetic; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000235:genetics*; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D000077210:Sunitinib